Efficacy and safety of zonisamide: results of a multicenter study

✍ Scribed by I.E. Leppik; L.J. Willmore; R.W. Homan; G. Fromm; K.J. Oommen; J.K. Penry; J.C. Sackellares; D.B. Smith; R.P. Lesser; J.D. Wallace; J.L. Trudeau; L.K. Lamoreaux; M. Spenser

• Publisher: Elsevier Science
• Year: 1993
• Tongue: English
• Weight: 925 KB
• Volume: 14
• Category: Article
• ISSN: 0920-1211
• DOI: 10.1016/0920-1211(93)90021-x

✦ Synopsis

The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historicalcontrolled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13--16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; i!3 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250--477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.